Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.

• ISIN: FR0010425595
• Date: 12/31/2025
• Total shares: 100,339,441
• Total voting rights: 105,576,356

Contact details for media and investor relations were provided for further information.

News Market Reaction – CLLS

-3.08%

4 alerts

-3.08% Session close to close

$326.91M Market Cap

0.3x Rel. Volume

In the Jan 6 session, CLLS declined 3.08%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement provides updated figures on Cellectis’s share capital and total voting rights as o...

Analysis

This announcement provides updated figures on Cellectis’s share capital and total voting rights as of December 31, 2025, continuing its routine monthly disclosures. These data points help investors track the capital structure and voting base over time. In the recent past, more meaningful price moves were associated with clinical data, earnings, and arbitration developments, so future attention may focus on upcoming trial milestones and corporate updates rather than this administrative report.

Key Figures

Total shares: 100,339,441 Total voting rights: 105,576,356

2 metrics

Total shares 100,339,441 Share capital as of 12/31/2025

Total voting rights 105,576,356 Voting rights as of 12/31/2025

Historical Context

5 past events · Latest: Dec 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 15	Arbitration outcome	Neutral	+2.4%	Arbitral Tribunal decision partially terminating a license and dismissing other claims.
Dec 08	Clinical data update	Positive	-2.5%	ASH 2025 Phase 1 NATHALI-01 eti-cel data with high ORR and CR rates.
Dec 03	Capital/voting report	Neutral	+3.6%	Monthly disclosure of total shares and voting rights as of November 30, 2025.
Nov 19	Scientific publication	Positive	+7.1%	Nature Communications paper on non-viral CssDNA gene insertion with high efficiency.
Nov 07	Earnings and update	Positive	+11.3%	Q3 2025 results with multiple CAR-T efficacy data points and stronger revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows strong positive reactions to major clinical and earnings updates, while an ASH 2025 clinical poster saw a negative move, indicating occasional divergence even on seemingly positive data.

Recent Company History

Over the last few months, Cellectis issued several clinically and strategically important updates. The Q3 2025 earnings and business update on Nov 7, 2025 and the non-viral gene editing paper on Nov 19, 2025 both saw notable positive price reactions. A routine monthly share-capital disclosure on Dec 3, 2025 also coincided with a gain. By contrast, an apparently positive ASH 2025 eti-cel update on Dec 8, 2025 was followed by a price decline, showing that market reception to clinical data has not been uniformly aligned.

Key Terms

isin

1 terms

isin financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Jan. 05, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
12/31/2025	100,339,441	105,576,356

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachment

• Voting_Rights_PR_December_2025_EN

FAQ

What are Cellectis (CLLS) total shares and voting rights as of December 31, 2025?

As of 12/31/2025, Cellectis reported 100,339,441 shares and 105,576,356 total voting rights.

Which market and ISIN does the Cellectis (CLLS) share capital notice reference?

The notice references Euronext Growth and ISIN FR0010425595.

Where can investors get more information about Cellectis (CLLS) share capital on January 5, 2026?

Investors can contact the provided investor relations email at investors@cellectis.com or the CFO contact listed in the release.

Does the December 31, 2025 report for Cellectis (CLLS) show a change in share count or voting rights?

The release provides the recorded totals for 12/31/2025; it does not include prior-period figures or an explicit change comparison.

Who are the media contacts listed for Cellectis (CLLS) regarding the December 2025 voting rights report?

Media contacts listed are Pascalyne Wilson and Patricia Sosa Navarro with phone numbers provided in the notice.